American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
Vaxart, Inc.
$0.59
+1.72%
OTC: VXRT · 15-min delayed
$237.3MRevenue · FY2025
$16.3MNet income
VXRTOTC
2004Founded
About Vaxart, Inc.
VAXART INC
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Revenue FY2025
- $237.3M
- Net income
- $16.3M
- Total assets
- $186.1M
- Operating margin
- -231.0%
- Net margin
- -233.3%
Source: SEC EDGAR · updated Jun 7, 2026
Multi-year
Revenue & profit trend
FY2020
FY2021
FY2022
FY2023
FY2024
Revenue Net income
FY 2024
Financial statements
Income statement
- Revenue
- $28.7M
- Operating expenses
- $95.0M
- Operating income
- -$66.3M
- Income tax
- $260.0K
- Net income
- -$66.9M
- EPS (basic)
- $-0.33
Balance sheet
- Total assets
- $166.4M
- Current assets
- $68.3M
- Total liabilities
- $107.5M
- Current liabilities
- $90.9M
- Shareholders’ equity
- $58.9M
Cash flow
- Operating cash flow
- -$44.8M
- Investing cash flow
- -$21.3M
- Financing cash flow
- $56.6M
- Net cash flow
- -$9.5M
Statements via Polygon.io (SEC filings)
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Profitable — net income of $16.3M in FY2025.
- Revenue grew 609% from FY2020 to FY2024.
- Trading 26% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Vaxart, Inc..
Write a review
Newsroom
News about Vaxart, Inc.
3 Stocks Under $5 With Strong Analyst Upside Potential
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025
Concerned Vaxart Stockholders Condemn Board’s Decision to Adjourn Reverse Stock Split Vote at Special Meeting
Vaxart Announces Adjournment of Special Meeting of Stockholders
News & sentiment via Polygon.io
Explore
Browse all →
